Jazz Set To Expand Ziihera Market In Gastroesophageal Cancer

 
• By Alaric DeArment
  
Jazz Pharmaceuticals
Jazz announced positive results from its Phase III trial of Ziihera in gastroesophageal adenocarcinoma. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D